Skip to main content

Belimumab

Pronunciation: be-lim-ue-mab
Generic name: belimumab
Brand name: Benlysta
Dosage form: single-dose vial for intravenous infusion (120 mg/vial, 400 mg/vial), prefilled syringe for subcutaneous use (200 mg/mL), prefilled autoinjector for subcutaneous use (200 mg/mL)
Drug class: Selective immunosuppressants

Medically reviewed by Carmen Pope, BPharm. Last updated on Jun 30, 2025.

What is belimumab?

Belimumab is used to treat active systemic lupus erythematosus (SLE) or active lupus nephritis in adults and children 5 years of age and older. The brand name is Benlysta. It is given by subcutaneous injection or intravenous infusion every 1 to 2 weeks, depending on the age of the patient.

Belimumab works by targeting and blocking a protein called B-lymphocyte stimulator (BLyS) that helps B cells survive and produce antibodies. In lupus, B cells are overactive and produce harmful autoantibodies that attack healthy tissue. By blocking BLyS, belimumab reduces the survival of B cells, decreases the production of autoantibodies, and helps control the overactive immune response. This improves symptoms such as fatigue, and reduces flares associated with SLE and lupus nephritis. 

Belimumab gained FDA approval on March 9, 2011, under the brand name Benlysta, made by GlaxoSmithKline LLC. There is no generic or biosimilar.

FDA approvals and uses

Belimumab is used to treat adults and children aged 5 years and older with:

Belimumab should not be used in patients with severe active central nervous system lupus, as its effectiveness has not been evaluated.

The autoinjector can be used for subcutaneous administration in adults and children aged 5 and older, weighing at least 15 kg. The prefilled syringe has not been studied in children less than 18 years of age.

Side effects

The most common side effects of belimumab are:

Serious side effects and warnings

Belimumab may cause the following serious side effects:

Live vaccines should not be given concurrently with this medicine.

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before receiving

Do not receive a belimumab injection or infusion if you are allergic to the active ingredient belimumab, Benlysta, or any of the inactive ingredients in the injection or infusion.

Before receiving, tell your healthcare provider about all your medical conditions, including if you:

This medicine may increase your risk of certain cancers by changing the way your immune system works. Ask your doctor about your risk.

Some people have thoughts about suicide while using belimumab. Your doctor will need to check your progress at regular visits. Your family or other caregivers should also be alert to changes in your mood or symptoms.

Pregnancy

It is not known if belimumab injection or infusion will harm your unborn baby or affect its immune system. You should talk to your healthcare provider about whether to prevent pregnancy while on belimumab. If you choose to prevent pregnancy, you should use an effective method of birth control while receiving belimumab and for at least 4 months after the final dose.

Tell your healthcare provider right away if you become pregnant during your treatment with belimumab or if you think you may be pregnant. If you become pregnant while receiving belimumab, talk to your healthcare provider about enrolling in the Benlysta Pregnancy Registry. You can enroll in this registry by calling 1-877-311-8972 or going to MotherToBaby to enroll. The purpose of this registry is to collect information about you and your baby's health.

Breastfeeding

It may not be safe to breastfeed while using belimumab. Ask your doctor about any risks.

How is belimumab administered?

Belimumab may be administered into a vein by a healthcare provider (this is called an IV infusion) or given under the skin (this is called subcutaneously), either by self-administration or by a healthcare provider.

Intravenous administration

You will be given your belimumab infusion by a healthcare provider through a needle placed in a vein (IV infusion).

Subcutaneous administration

Belimumab for subcutaneous injection can be self-administered or given by a caregiver.

Belimumab injection for SC use may be prescribed as a single-dose autoinjector or as a single-dose prefilled syringe.

Dosing information

The dose of belimumab depends on the age of the patient and administration (IV or SC).

Intravenous Dose of Belimumab for SLE or Lupus Nephritis (Adults and Children)

Subcutaneous Dose of Belimumab for SLE (Adults)

Subcutaneous Dose of Belimumab for SLE (Child 5 years and older)

Subcutaneous Dose of Belimumab for Lupus Nephritis (Adults)

Subcutaneous Dose of Belimumab for Lupus Nephritis (Child 5 years and older)

Belimumab J Code

Belimumab J code is J0490 (Injection, Benlysta, 10 mg)

Belimumab is available as:

What happens if I miss a dose?

If you miss your dose of belimumab on your planned day, inject a dose as soon as you remember. Then, inject your next dose at your regularly scheduled time or continue dosing based on the new day of injection.

Do not use 2 injections on the same day. In case you are not sure when to inject belimumab, call your healthcare provider.

Call your doctor for instructions if you miss an appointment for an intravenous infusion of belimumab.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Belimumab Prescribing Information

Review the belimumab Prescribing Information or belimumab Package Insert for more detailed information about this medicine. Discuss any medical questions you have with your doctor or other health care provider. This is not all the information you need to know about this medicine for safe and effective use, and it does not take the place of talking to your doctor about your treatment.

What should I avoid while using belimumab?

Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.

Do not receive a "live" vaccine while using belimumab. The vaccine may not work as well and may not fully protect you from disease. Live vaccines include measles, mumps, rubella (MMR), rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster (shingles), and the nasal flu (influenza) vaccine.

What other drugs will affect belimumab?

Other drugs may interact with belimumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Research does not support using belimumab with other biologic treatments, such as rituximab, in people with SLE because of the increased incidence of serious infections and post-injection systemic reactions.

Does Belimumab interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Storage

Belimumab vials for intravenous infusion

Store belimumab vials for IV infusion in a refrigerator at 36°F to 46°F (2°C to 8°C). Store vials in the original carton until use to protect from light. Do not freeze. Avoid exposure to heat.

Belimumab autoinjectors and prefilled syringes for subcutaneous injection

Prior to dispensing and following dispensing. Refrigerate prefilled belimumab autoinjectors and prefilled syringes at 36°F to 46°F (2°C to 8°C). Keep the product in the original carton to protect it from light until the time of use. Do not freeze. Do not shake. Avoid exposure to heat.

Ingredients

Belimumab is only available as the brand name Benlysta.

Active ingredient: belimumab.

Benlysta inactive ingredients (intravenous): citric acid, polysorbate 80, sodium citrate, sucrose.

Benlysta inactive Ingredients (subcutaneous): L-arginine hydrochloride, L-histidine, L-histidine monohydrochloride, polysorbate 80, sodium chloride.

Manufacturer

GlaxoSmithKline LLC manufactures belimumab under the brand name Benlysta.

Belimumab Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for belimumab.

Benlysta (belimumab) - GlaxoSmithKline LLC
Formulation type Strength
Autoinjector 200 mg/mL
Pre-Filled Syringe 200 mg/mL
Single-Dose Vial 120 mg
Single-Dose Vial 400 mg

View Benlysta information in detail.

Popular FAQ

What is the difference between Benlysta and Saphnelo?

Benlysta and Saphnelo are both targeted treatments, but they target different parts of the immune system that are particularly overactive in lupus. Benlysta targets and blocks the activity of a type of white blood cell called a B cell, which produces antibodies that attack tissue, causing symptoms of SLE. It is classified as a B-lymphocyte stimulator (BLyS)-specific inhibitor. Saphnelo targets the type I interferon receptor and inhibits the activity of type 1 interferons. Activation of the interferon system is a common underlying characteristic of SLE that leads to the immune system being constantly “switched on”, contributing to SLE symptoms. Saphnelo is classified as a type 1 interferon receptor antagonist. Benlysta was first approved in 2011 and Saphnelo was approved in 2021. Continue reading

How does Benlysta work for lupus?

Benlysta works by attaching to a specific protein, called B-lymphocyte stimulator (BLyS), preventing it from binding to its receptors on B cells. BLyS is important for the growth and development of B cells, and B cells have a crucial role in the development of lupus. Certain B cells, called autoreactive B-cells, stay in the body for longer than they should, producing autoantibodies that target important cellular components, such as DNA, causing disease flares. By binding to BLyS, Benlysta prevents the survival of B-cells and their differentiation into immunoglobulin-producing plasma cells.

Benlysta is a biologic therapy, not a steroid. It may be called a B-cell depleting therapy or a selective immunosuppressant. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.